{"id":"NCT02589275","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients","officialTitle":"A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-04","primaryCompletion":"2016-09-28","completion":"2016-09-28","firstPosted":"2015-10-28","resultsPosted":"2024-12-11","lastUpdate":"2025-02-20"},"enrollment":375,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Fibromyalgia"],"interventions":[{"type":"DRUG","name":"TNX-102 SL Tablet 2.8 mg","otherNames":["cyclobenzaprine"]}],"arms":[{"label":"TNX-102 SL Tablet 2.8 mg","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of Fibromyalgia (FM). Patients recruits into this trial are those who have successfully completed the double-blind studies; TNX-CY-F301 and TNX-CY-F302.\n\nPatients will not be made aware of the therapy they received during the double-blind study.","primaryOutcome":{"measure":"Newly Emergent Adverse Events","timeFrame":"Up to 3 months from first dose","effectByArm":[{"arm":"TNX-TNX","deltaMin":77,"sd":null},{"arm":"PBO-TNX","deltaMin":132,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":170},"commonTop":["Hypoaesthesia Oral","Product Taste Abnormal","Parasthesia Oral","Tongue Discomfort"]}}